Avalo Therapeutics estimates $98M year-end cash

Avalo Therapeutics, Inc. reported that it estimates having approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025, based on figures shared in an updated investor presentation.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. reported that it estimates having approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025, based on figures shared in an updated investor presentation.

The company emphasized that this cash estimate is unaudited, preliminary and does not include full details of its financial condition or results for the year, which will be provided in its future annual report. Avalo also made the updated investor presentation available on its website and attached it as an exhibit to this report for use in meetings with investors.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What cash balance did Avalo Therapeutics (AVTX) estimate at year-end 2025?

Avalo Therapeutics estimated it had approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025.

Is Avalo Therapeutics' $98 million cash figure for December 31, 2025 audited?

No. The company stated the $98 million cash, cash equivalents and short-term investments figure is unaudited and preliminary.

Where can investors find Avalo Therapeutics' updated investor presentation?

The updated investor presentation is posted on the company’s website and is attached as Exhibit 99.1 to this report.

Will Avalo Therapeutics (AVTX) include full 2025 financial results with this disclosure?

No. The company noted that full financial condition and results for the year ended December 31, 2025 will be included in its future Form 10-K.

How is the information in Item 2.02 of this Avalo Therapeutics 8-K treated under the Exchange Act?

The company stated that the information in Item 2.02 is being furnished, not filed, and is not subject to Section 18 liabilities, nor incorporated by reference unless specifically stated.

How does Avalo Therapeutics plan to use the updated investor presentation?

Avalo Therapeutics indicated the investor presentation may be used from time to time in meetings with investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:53 AM Learn about SEC filing dates

0001534120false00015341202026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549  

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

AVALO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)  

Delaware

(State or other jurisdiction of incorporation)

001-37590						45-0705648
(Commission File Number)						(IRS Employer Identification No.)

1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087

(Address of principal executive offices) (Zip Code)

Registrant’s Telephone Number, Including Area Code: (410) 522-8707

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 Par Value			AVTX			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On January 12, 2026, Avalo Therapeutics, Inc. (the “Company”) disclosed in an updated investor presentation posted on its website that the Company estimates it had approximately $98 million of cash, cash equivalents and short-term investments as of December 31, 2025.

The information contained in Item 2.02 of this Current Report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2025 and its results of operations for the year ended December 31, 2025. The Company’s actual results for the year ended December 31, 2025 will be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and may differ materially from the above estimate.

The information contained in Item 2.02 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01    Other Events.

The Company has posted on its website an updated investor presentation (the “Investor Presentation”). The Investor Presentation will be used from time to time in meetings with investors. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits:

Exhibit No.						Description
99.1						Investor Presentation.
104						The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									AVALO THERAPEUTICS, INC.
Date: January 12, 2026						By:			/s/ Christopher Sullivan
									Christopher Sullivan
									Chief Financial Officer

2